Gene expression profiling of dilated cardiomyopathy in older male EP4 knockout mice

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 298, Issue 2, 2010, Pages

  Harding, Pamela ^a   Yang, Xiao Ping ^a   Yang, James ^a   Shesely, Ed ^a   He, Quan ^a   LaPointe, Margot C ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

Growth differentiation factor 15; Heart; Remodeling

Indexed keywords

CHEMOKINE; COLLAGEN; CYTOKINE; GROWTH DIFFERENTIATION FACTOR 15; PROSTAGLANDIN E RECEPTOR;

AGED; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; ECHOCARDIOGRAPHY; EP4 GENE; FEMALE; GENE EXPRESSION PROFILING; HEART EJECTION FRACTION; HEART FUNCTION; HEART MUSCLE FIBROSIS; INFLAMMATION; KNOCKOUT MOUSE; MALE; MOUSE; NEWBORN; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RECEPTOR GENE; RNA EXTRACTION;

AGING; ANIMALS; CARDIOMYOPATHY, DILATED; CHEMOKINES; COLLAGEN; CYTOKINES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION PROFILING; GROWTH DIFFERENTIATION FACTOR 15; MACROPHAGES; MALE; MICE; MICE, KNOCKOUT; MYOCYTES, CARDIAC; PHENOTYPE; RECEPTORS, PROSTAGLANDIN E; SEX CHARACTERISTICS; STROKE VOLUME;

EID: 74949123046     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00746.2009     Document Type: Article

References (42)

1. Arber S, Hunter JJ, Ross JJ, Hongo M, Sansig G, Borg J, Perriard JC, Chien KR, Caroni P. MLP-deficient mice exhibit a disruption of cardiac cytoarchitectural organization, dilated cardiomyopathy, and heart failure. Cell 88: 393-403, 1997.
2. Barth AS, Kuner R, Buness A, Ruschhaupt M, Merk S, Zwermann L, Kaab S, Kreuzer E, Steinbeck G, Mansmann U, Poustka A, Nabauer M, Sultmann H. Identification of a common gene expression signature in dilated cardiomyopathy across independent microarray studies. J Am Coll Cardiol 48: 1610-1617, 2006.
3. Bryant D, Becker L, Richardson J, Shelton J, Franco F, Peshock R, Thompson M, Giroir B. Cardiac failure in transgenic mice with myo-cardial expression of tumor necrosis factor-alpha. Circulation 97: 1375-1381, 1998.
4. Buerger A, Rozhitskaya O, Sherwood MC, Dorfman AL, Bisping E, Abel ED, Pu WT, Izumo S, Jay PY. Dilated cardiomyopathy resulting from high-level myocardial expression of Cre-recombinase. J Card Fail 12: 392-398, 2006.
5. Burkett EL, Hershberger RE. Clinical and genetic issues in familial dilated cardiomyopathy. J Am Coll Cardiol 45: 969-981, 2005.
6. Colbert MC, Hall DG, Kimball TR, Witt SA, Lorenz JN, Kirby ML, Hewett TE, Klevitsky R, Robbins J. Cardiac compartment-specific overexpression of a modified retinoic acid receptor produces dilated cardiomyopathy and congestive heart failure in transgenic mice. J Clin Invest 100: 1958-1968, 1997.
7. Deschamps AM, Yarbrough WM, Squires CE, Allen RA, McClister DM, Dowdy KB, McLean JE, Mingoia JT, Sample JA, Mukherjee R, Spinale FG. Trafficking of the membrane type-1 matrix metalloproteinase in ischemia and reperfusion: relation to interstitial membrane type-1 matrix metalloproteinase activity. Circulation 111: 1166-1174, 2005.
8. Eggers KM, Kempf T, Allhoff T, Lindahl B, Wallentin L, Wollert KC. Growth-differentiation factor-15 for early risk stratification in patients with acute chest pain. Eur Heart J 29: 2327-2335, 2008.
9. Forleo C, Resta N, Sorrentino S, Guida P, Manghisi A, De L, V, Romito R, Iacoviello M, De Tommasi E, Troisi F, Rizzon B, Guanti G, Rizzon P, Pitzalis MV. Association of beta-adrenergic receptor polymorphisms and progression to heart failure in patients with idiopathic dilated cardiomyopathy. Am J Med 117: 451-458, 2004.
10. Freeman K, Colon-Rivera C, Olsson MC, Moore RL, Weinberger HD, Grupp IL, Vikstrom KL, Iaccarino G, Koch WJ, Leinwand LA. Progression from hypertrophic to dilated cardiomyopathy in mice that express a mutant myosin transgene. Am J Physiol Heart Circ Physiol 280: H151-H159, 2001.
11. Guo C, Piacentini L. Type I collagen-induced MMP-2 activation coincides with up-regulation of membrane type 1-matrix metalloproteinase and TIMP-2 in cardiac fibroblasts. J Biol Chem 278: 46699 - 46708, 2003.
12. Gupta MP. Factors controlling cardiac myosin-isoform shift during hypertrophy and heart failure. J Mol Cell Cardiol 43: 388 - 403, 2007.
13. Haddad GE, Saunders LJ, Crosby SD, Carles M, del Monte F, King K, Bristow MR, Spinale FG, Macgillivray TE, Semigran MJ, Dec GW, Williams SA, Hajjar RJ, Gwathmey JK. Human cardiac-specific cDNA array for idiopathic dilated cardiomyopathy: sex-related differences. Physiol Genomics 33: 267-277, 2008.
14. Hishikari K, Suzuki J, Ogawa M, Isobe K, Takahashi T, Onishi M, Takayama K, Isobe M. Pharmacological activation of the prostaglandin E2 receptor EP4 improves cardiac function after myocardial ischaemia/ reperfusion injury. Cardiovasc Res 81: 123-132, 2009.
15. Hori T, Naishiro Y, Sohma H, Suzuki N, Hatakeyama N, Yamamoto M, Sonoda T, Mizue Y, Imai K, Tsutsumi H, Kokai Y. CCL8 is a potential molecular candidate for the diagnosis of graft-versus-host disease. Blood 111: 4403-4412, 2008.
16. Jacoby JJ, Kalinowski A, Liu MG, Zhang SS, Gao Q, Chai GX, Ji L, Iwamoto Y, Li E, Schneider M, Russell KS, Fu XY. Cardiomyocyterestricted knockout of STAT3 results in higher sensitivity to inflammation, cardiac fibrosis, and heart failure with advanced age. Proc Natl Acad Sci USA 100: 12929-12934, 2003.
17. Kadokami T, McTiernan CF, Kubota T, Frye CS, Feldman AM. Sex-related survival differences in murine cardiomyopathy are associated with differences in TNF-receptor expression. J Clin Invest 106: 589-597, 2000.
18. Kaufman BD, Auerbach S, Reddy S, Manlhiot C, Deng L, Prakash A, Printz BF, Gruber D, Papavassiliou DP, Hsu DT, Sehnert AJ, Chung WK, Mital S. RAAS gene polymorphisms influence progression of pediatric hypertrophic cardiomyopathy. Hum Genet 122: 515-523, 2007.
19. Kempf T, Eden M, Strelau J, Naguib M, Willenbockel C, Tongers J, Heineke J, Kotlarz D, Xu J, Molkentin JD, Niessen HW, Drexler H, Wollert KC. The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury. Circ Res 98: 351-360, 2006.
20. Kempf T, von Haehling S, Peter T, Allhoff T, Cicoira M, Doehner W, Ponikowski P, Filippatos GS, Rozentryt P, Drexler H, Anker SD, Wollert KC. Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J Am Coll Cardiol 50: 1054-1060, 2007.
21. Kempf T, Wollert KC. Growth-differentiation factor-15 in heart failure. Heart Fail Clin 5: 537-547, 2009.
22. Kubota T, Miyagishima M, Frye CS, Alber SM, Bounoutas GS, Kadokami T, Watkins SC, McTiernan CF, Feldman AM. Overexpression of tumor necrosis factor-alpha activates both anti- and pro-apoptotic pathways in the myocardium. J Mol Cell Cardiol 33: 1331-1344, 2001.
23. Magga J, Vuolteenaho O, Tokola H, Marttila M, Ruskoaho H. B-type natriuretic peptide: a myocyte-specific marker for characterizing loadinduced alterations in cardiac gene expression. Ann Med 30, Suppl 1: 39-45, 1998.
24. Matsumura S, Iwanaga S, Mochizuki S, Okamoto H, Ogawa S, Okada Y. Targeted deletion or pharmacological inhibition of MMP-2 prevents cardiac rupture after myocardial infarction in mice. J Clin Invest 115: 599-609, 2005.
25. McClung HM, Thomas SL, Osenkowski P, Toth M, Menon P, Raz A, Fridman R, Rempel SA. SPARC upregulates MT1-MMP expression, MMP-2 activation, and the secretion and cleavage of galectin-3 in U87MG glioma cells. Neurosci Lett 419: 172-177, 2007.
26. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 69: 562-573, 2006.
27. Nieminen MS, Harjola VP, Hochadel M, Drexler H, Komajda M, Brutsaert D, Dickstein K, Ponikowski P, Tavazzi L, Follath F, Lopez-Sendon JL. Gender related differences in patients presenting with acute heart failure. Results from EuroHeart Failure Survey II. Eur J Heart Fail 10: 140-148, 2008.
28. Ogawa M, Suzuki J, Kosuge H, Takayama K, Nagai R, Isobe M. The mechanism of anti-inflammatory effects of prostaglandin E2 receptor 4 activation in murine cardiac transplantation. Transplantation 87: 1645-1653, 2009.
29. Ogawa T, Linz W, Stevenson M, Bruneau BG, Kuroski de Bold ML, Chen JH, Eid H, Scholkens BA, de Bold AJ. Evidence for loaddependent and load-independent determinants of cardiac natriuretic peptide production. Circulation 93: 2059-2067, 1996.
30. Perkins MJ, Van Driest SL, Ellsworth EG, Will ML, Gersh BJ, Ommen SR, Ackerman MJ. Gene-specific modifying effects of pro-LVH polymorphisms involving the renin-angiotensin-aldosterone system among 389 unrelated patients with hypertrophic cardiomyopathy. Eur Heart J 26: 2457-2462, 2005.
31. Qian JY, Harding P, Liu Y, Shesely E, Yang XP, LaPointe MC. Reduced cardiac remodeling and function in cardiac-specific EP4 receptor knockout mice with myocardial infarction. Hypertension 51: 560-566, 2008.
32. Satoh M, Matter CM, Ogita H, Takeshita K, Wang CY, Dorn GW, Liao JK. Inhibition of apoptosis-regulated signaling kinase-1 and prevention of congestive heart failure by estrogen. Circulation 115: 3197-3204, 2007.
33. Shimizu K, Mitchell RN. The role of chemokines in transplant graft arterial disease. Arterioscler Thromb Vasc Biol 28: 1937-1949, 2008.
34. Shin JJ, Glickstein LJ, Steere AC. High levels of inflammatory chemokines and cytokines in joint fluid and synovial tissue throughout the course of antibiotic-refractory lyme arthritis. Arthritis Rheum 56: 1325-1335, 2007.
35. Spinale FG, Coker ML, Heung LJ, Bond BR, Gunasinghe HR, Etoh T, Goldberg AT, Zellner JL, Crumbley AJ. A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation 102: 1944-1949, 2000.
36. Sussman MA, Welch S, Gude N, Khoury PR, Daniels SR, Kirkpatrick D, Walsh RA, Price RL, Lim HW, Molkentin JD. Pathogenesis of dilated cardiomyopathy: molecular, structural, and population analyses in tropomodulin-overexpressing transgenic mice. Am J Pathol 155: 2101-2113, 1999.
37. Winer J, Jung CK, Shackel I, Williams PM. Development and validation of real-time quantitative reverse transcriptase-polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro. Anal Biochem 270: 41-49, 1999.
38. Wollert KC. Growth-differentiation factor-15 in cardiovascular disease: from bench to bedside, and back. Basic Res Cardiol 102: 412- 415, 2007.
39. Xiao CY, Yuhki K, Hara A, Fujino T, Kuriyama S, Yamada T, Takayama K, Takahata O, Karibe H, Taniguchi T, Narumiya S, Ushikubi F. Prostaglandin E2 protects the heart from ischemia-reperfusion injury via its receptor subtype EP4. Circulation 109: 2462-2468, 2004.
40. Xu J, Kimball TR, Lorenz JN, Brown DA, Bauskin AR, Klevitsky R, Hewett TE, Breit SN, Molkentin JD. GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation. Circ Res 98: 342-350, 2006.
41. Yang XP, Liu YH, Mehta D, Cavasin MA, Shesely E, Xu J, Liu F, Carretero OA. Diminished cardioprotective response to inhibition of angiotensin-converting enzyme and angiotensin II type 1 receptor in B2 kinin receptor gene knockout mice. Circ Res 88: 1072-1079, 2001.
42. Zavadzkas JA, Plyler RA, Bouges S, Koval CN, Rivers WT, Beck CU, Chang EI, Stroud RE, Mukherjee R, Spinale FG. Cardiac-restricted overexpression of extracellular matrix metalloproteinase inducer causes myocardial remodeling and dysfunction in aging mice. Am J Physiol Heart Circ Physiol 295: H1394-H1402, 2008.